Skip to main content
ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. logo

ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD. — Investor Relations & Filings

Ticker · 300009 ISIN · CNE100000GY2 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,016 across all filing types
Latest filing 2019-04-24 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300009

About ANHUI ANKE BIOTECHNOLOGY (GROUP)CO.,LTD.

https://www.ankebio.com

Anhui Anke Biotechnology (Group) Co., Ltd. is a high-tech enterprise specializing in the research, development, production, and commercialization of biopharmaceutical products. The company focuses on genetic engineering, cell therapy, and precision medicine. Its core product portfolio includes recombinant human growth hormone (rhGH) marketed under the brand Ansomone, and recombinant human interferon alpha-2b known as Anterferon. Anke Bio also develops diagnostic reagents, including biochemical and molecular diagnostic kits, and provides services in the fields of oncology and reproductive health. The company maintains a strong emphasis on innovation through its dedicated R&D centers, aiming to provide advanced therapeutic solutions for growth disorders, viral infections, and various cancers. Its operations span the entire value chain from basic research to clinical application and market distribution.

Recent filings

Filing Released Lang Actions
关于第六届监事会第十八次会议决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of resolutions passed at the 18th meeting of the 6th Supervisory Board of Anhui Anke Biotechnology (Group) Co., Ltd. It includes voting results on several agenda items, including approval of the company's 2019 first quarter report and election of the Supervisory Board chairman. The document is short (1457 characters) and states that the full 2019 first quarter report can be found on the designated disclosure website, indicating this is not the report itself but an announcement of meeting resolutions and voting outcomes. This fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2019-04-24 Chinese
关于使用募集资金置换预先投入募投项目自筹资金的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Anhui Anke Biotechnology Engineering (Group) Co., Ltd. regarding the use of raised funds to replace self-raised funds previously invested in projects. It includes details about the fundraising, approvals from the board and supervisory committee, independent director opinions, and verification by an accounting firm. The document is relatively short (3166 characters) and primarily serves as a formal disclosure of a financing activity related to the company's capital structure and use of funds. It does not contain comprehensive financial statements or detailed financial performance data. Therefore, it is best classified as a Capital/Financing Update (CAP).
2019-04-24 Chinese
独立董事对相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's use of raised funds to replace previously invested self-raised funds in a project. It references regulatory guidelines and an audit firm's verification report but does not contain financial statements or comprehensive financial data. The document is relatively short (830 characters) and focuses on governance and compliance opinions rather than financial results or detailed reports. This fits best under Regulatory Filings (RNS) as it is a regulatory compliance-related announcement and not a full audit report or annual/interim report.
2019-04-24 Chinese
关于2018年度股东大会决议的公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a detailed announcement of the resolutions passed at the 2018 Annual General Meeting (AGM) of 安徽安科生物工程（集团）股份有限公司. It includes voting results on various proposals such as the 2018 board report, financial report, profit distribution plan, appointment of auditors, amendments to the company charter, and election of a new supervisor. The document also contains information about the meeting's attendance, voting procedures, and legal opinions confirming the validity of the meeting and resolutions. The content is focused on the outcomes and decisions made during the AGM rather than the full annual report or financial statements themselves. Therefore, this document fits the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length (9552 characters) and detailed voting results support this classification rather than a brief announcement or a full annual report.
2019-04-19 Chinese
2018年年度股东大会之法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the 2018 Annual General Meeting (AGM) of Anhui Anke Bioengineering (Group) Co., Ltd. It details the legality and compliance of the AGM procedures, attendance, voting, and resolutions passed. The document does not contain financial statements or results but focuses on the legal validation of the AGM process and outcomes. It is not the AGM presentation materials themselves but a legal opinion related to the AGM. Given the content and purpose, this fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it confirms the legality and results of the shareholder meeting and voting.
2019-04-19 Chinese
关于完成工商变更登记的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the completion of business registration changes following a non-public stock issuance approved by the China Securities Regulatory Commission. It includes details about the updated business license and registration information. The document is short (1090 characters) and serves as an official notice of a corporate registration update rather than a financial report or detailed filing. It does not contain financial statements, audit information, or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-04-08 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.